Abbott AxSYM U.S. Presence May Give Firm Edge Over BNP Competitors
This article was originally published in The Gray Sheet
Executive Summary
Abbott will try to leverage its installed U.S. base of 5,000 AxSYM automated analyzers to gain a competitive advantage over Bayer Diagnostics as each firm prepares a 2003 launch of a B-type natriuretic peptide (BNP) test to help diagnose congestive heart failure